… from the IMerge phase 3 trial of imetelstat in lower-risk myelodysplastic … for a sequential, patient-centered treatment approach to enhance quality of …

Panelists discuss the debate on optimal timing for initiating therapies in lower-risk myelodysplastic syndromes, balancing early intervention to improve quality of life and prevent complications against a conservative approach favoring treatment initiation …

… MD, a professor of medicine at the Icahn School … Tisch Cancer Institute, discussed the safety profile of imetelstat (Rytelo … Importantly, no patients discontinued treatment due to hematologic toxicity, … -term therapy. The trial investigators concluded that the …

… phase 2/3 IMerge trial (NCT02598661).1 The data, which … June 2024, the FDA approved imetelstat for the treatment of adult patients with … ;/www.fda.gov/drugs/;resources-information-approved-drugs/fda-approves-imetelstat-low-intermediate …

… MD, a professor of medicine at the Icahn School … of Excellence for Blood Cancers and Myeloid Disorders, … #47;1b IMproveMF trial (NCT05371964) investigating imetelstat (Rytelo) plus ruxolitinib … explained. The durability of treatment, patient retention on therapy …

… PharmD, BCOP, from Michigan Medicine in Ann Arbor, Michigan … [MF]—looking at new drugs like imetelstat [Rytelo; Geron Corporation] … advances currently shaping the treatment of hematologic disorders … transformation to secondary cancers or reducing the …

… the Moffitt Cancer Center; as well as a professor in medicine … sciences in the College of Medicine at the University of South … IMerge trial (NCT02598661) demonstrated that imetelstat retained clinical activity across various prior treatment …

Hematologists Highlight Notable Insights From the 2025 EHA Congress Post Hoc Analysis Shows Imetelstat Drives Benefit in RS-Negative, Lower-Risk MDS Bexobrutideg Is Tolerable and Yields High Response Rates in Relapsed/Refractory Waldenström …

… phase 2/3 IMerge trial (NCT02598661).1 The data, which … June 2024, the FDA approved imetelstat for the treatment of adult patients with … ;/www.fda.gov/drugs/;resources-information-approved-drugs/fda-approves-imetelstat-low-intermediate …

… Department, Moffitt Cancer Center. “While imetelstat is already playing … Vice President and Chief Medical Officer of Geron. … commercializing RYTELO (imetelstat) for the treatment of certain patients … ongoing clinical trials, including the IMpactMF trial; (j) …